MedTrace Logo

Metabolic Consequences of Gastrointestinal Surgery

NCT02836353 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2019-04-02

No results posted yet for this study

Summary

Surgery on the gastrointestinal (GI) tract results in profound changes to the metabolic profile. This is well described, including the rapid resolution of diabetes seen after bariatric surgery. The underlying pathophysiology, and incidence in lean patients undergoing surgery for cancer, is somewhat less described. The investigators plan to assess the symptomatic and glycaemic profile, as well as causative pathways, for metabolic symptoms in patients after surgery on the GI tract. The investigators will use glucose tolerance tests, physiological challenges with somatostatin analogues and antibiotics, and assess tissue transcriptomic changes.

Conditions

  • Gastrectomy
  • Oesophagectomy
  • Dumping Syndrome
  • Hypoglycaemia

Interventions

DRUG

Somatostatin

Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test

DRUG

Rifaximin

1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Geoffrey P Roberts, MA BM BCh · University of Cambridge

  • Fiona M Gribble, PhD · University of Cambridge

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-03-11
Completion
2019-03-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02836353 on ClinicalTrials.gov